{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:31:33Z","timestamp":1787671893125,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00210-026-05546-9","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T03:31:44Z","timestamp":1780889504000},"page":"18227-18237","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A real-world disproportionality analysis of dupilumab safety in children aged 0\u20135 years with atopic dermatitis"],"prefix":"10.1007","volume":"399","author":[{"given":"Liang","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huishan","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biqing","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"5546_CR1","doi-asserted-by":"crossref","unstructured":"Akinlade B, Guttman-Yassky E, de Bruin-Weller M et al (2019) Conjunctivitis in dupilumab clinical trials. British J Dermatol 181(3):459\u2013473","DOI":"10.1111\/bjd.17869"},{"issue":"6","key":"5546_CR2","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1093\/bjd\/ljae344","volume":"191","author":"MR Ardern-Jones","year":"2024","unstructured":"Ardern-Jones MR, Brown SJ, Flohr C et al (2024) An expert consensus on managing dupilumab-related ocular surface disorders in people with atopic dermatitis 2024. Br J Dermatol 191(6):865\u2013885","journal-title":"Br J Dermatol"},{"key":"5546_CR3","doi-asserted-by":"crossref","unstructured":"Bakker DS, Ariens LFM, van Luijk C et al (2019) Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis. Br J Dermatol 180:1248\u20131249","DOI":"10.1111\/bjd.17538"},{"issue":"4","key":"5546_CR4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR et al (1998) A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54(4):315\u2013321","journal-title":"Eur J Clin Pharmacol"},{"key":"5546_CR5","doi-asserted-by":"crossref","unstructured":"Bettuzzi T, Drucker A, Staumont-Sall\u00e9 D et al (2022) Adverse events associated with dupilumab in the World Health Organization pharmacovigilance database. J Am Acad Dermatol\u00a086:431\u2013433","DOI":"10.1016\/j.jaad.2021.09.050"},{"key":"5546_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14072487","author":"G Boscia","year":"2025","unstructured":"Boscia G, Spataro F, Desantis V et al (2025) Ocular side effects of Dupilumab: a comprehensive overview of the literature. J Clin Med. https:\/\/doi.org\/10.3390\/jcm14072487","journal-title":"J Clin Med"},{"issue":"3","key":"5546_CR7","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1590\/1984-0462\/;2017;35;3;00016","volume":"35","author":"DMV Bruscky","year":"2017","unstructured":"Bruscky DMV, Melo ACCD, Sarinho ESC (2017) Cross-cultural adaptation and validation of the Itching Severity Scale in children and adolescents with atopic dermatitis. Rev Paul Pediatr 35(3):244\u2013251","journal-title":"Rev Paul Pediatr"},{"key":"5546_CR8","doi-asserted-by":"crossref","unstructured":"Chu DK, Schneider L, Asiniwasis RN et al (2024) Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann of Allergy Asthma Immunol : Off Publ Am Coll Allergy Asthma Immunol 132(3):274\u2013312","DOI":"10.1016\/j.anai.2023.11.009"},{"key":"5546_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fdsfr.2023.1323057","volume":"3","author":"PM Cutroneo","year":"2023","unstructured":"Cutroneo PM, Sartori D, Tuccori M (2023) Conducting and interpreting disproportionality analysis derived from spontaneous reporting systems. Front Drug Saf Regul 3:1323057","journal-title":"Front Drug Saf Regul"},{"issue":"10","key":"5546_CR10","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jdcr.2019.07.020","volume":"5","author":"FSA de Beer","year":"2019","unstructured":"de Beer FSA, Bakker DS, Haeck I et al (2019) Dupilumab facial redness: Positive effect of itraconazole. JAAD Case Rep 5(10):888\u2013891","journal-title":"JAAD Case Rep"},{"issue":"3","key":"5546_CR11","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40257-019-00445-7","volume":"20","author":"LF Eichenfield","year":"2019","unstructured":"Eichenfield LF, Bieber T, Beck LA et al (2019) Infections in Dupilumab clinical trials in atopic dermatitis: a comprehensive pooled analysis. Am J Clin Dermatol 20(3):443\u2013456","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"5546_CR12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10(6):483\u2013486","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"5546_CR13","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B et al (2024) The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): development and statement. Drug Saf 47(6):575\u2013584","journal-title":"Drug Saf"},{"issue":"1","key":"5546_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-92330-z","volume":"15","author":"H Gao","year":"2025","unstructured":"Gao H, Cao L, Liu C (2025) Analysis and mining of Dupilumab adverse events based on FAERS database. Sci Rep 15(1):8597","journal-title":"Sci Rep"},{"issue":"3","key":"5546_CR15","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.jaip.2024.11.015","volume":"13","author":"D Garate","year":"2025","unstructured":"Garate D, Thang CJ, Chang CT et al (2025) Risk of malignancy associated with use of dupilumab versus other treatments in atopic dermatitis patients: A national database analysis. J Allergy Clin Immunol Pract 13(3):698\u2013701","journal-title":"J Allergy Clin Immunol Pract"},{"key":"5546_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9061982","author":"DH Jang","year":"2020","unstructured":"Jang DH, Heo SJ, Jung HJ et al (2020) Retrospective study of Dupilumab treatment for moderate to severe atopic dermatitis in Korea: efficacy and safety of Dupilumab in real-world practice. J Clin Med. https:\/\/doi.org\/10.3390\/jcm9061982","journal-title":"J Clin Med"},{"issue":"2","key":"5546_CR17","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jaad.2008.09.034","volume":"60","author":"Y Kubota","year":"2009","unstructured":"Kubota Y, Yoneda K, Nakai K et al (2009) Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: An open-label pilot study. J Am Acad Dermatol 60(2):212\u2013217","journal-title":"J Am Acad Dermatol"},{"key":"5546_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-025-00952-w","author":"RG Langley","year":"2025","unstructured":"Langley RG, Gherardi G, Coleman A et al (2025) The safety data of Dupilumab for the treatment of moderate\u2011to\u2011severe atopic dermatitis in infants, children, adolescents, and adults. Am J Clin Dermatol. https:\/\/doi.org\/10.1007\/s40257-025-00952-w","journal-title":"Am J Clin Dermatol"},{"key":"5546_CR19","doi-asserted-by":"crossref","unstructured":"Mennini M, Dahdah L, Fiocchi A (2017) Two phase 3 trials of dupilumab versus placebo in atopic dermatitis.\u00a0New Engl J Med 376:1090","DOI":"10.1056\/NEJMc1700366"},{"issue":"12","key":"5546_CR20","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s40264-017-0569-3","volume":"40","author":"V Newbould","year":"2017","unstructured":"Newbould V, Le Meur S, Goedecke T et al (2017) Medication errors: A characterisation of spontaneously reported cases in EudraVigilance. Drug Saf 40(12):1241\u20131248","journal-title":"Drug Saf"},{"issue":"Suppl 1","key":"5546_CR21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000370220","volume":"66","author":"S Nutten","year":"2015","unstructured":"Nutten S (2015) Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab 66(Suppl 1):8\u201316","journal-title":"Ann Nutr Metab"},{"issue":"5","key":"5546_CR22","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1016\/j.jaip.2022.12.018","volume":"11","author":"S Owji","year":"2023","unstructured":"Owji S, Ungar B, Dubin DP et al (2023) No association between dupilumab use and short-term cancer development in atopic dermatitis patients. J Allergy Clin Immunol Pract 11(5):1548\u20131551","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"5546_CR23","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/pde.14909","volume":"39","author":"AS Paller","year":"2022","unstructured":"Paller AS, Beck LA, Blauvelt A et al (2022) Infections in children and adolescents treated with Dupilumab in pediatric clinical trials for atopic dermatitis-a pooled analysis of trial data. Pediatr Dermatol 39(2):187\u2013196","journal-title":"Pediatr Dermatol"},{"key":"5546_CR24","doi-asserted-by":"crossref","unstructured":"Paller AS, Simpson EL, Siegfried EC et al (2022) Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England) 400(10356):908\u2013919","DOI":"10.1016\/S0140-6736(22)01539-2"},{"key":"5546_CR25","doi-asserted-by":"crossref","unstructured":"Paller AS, Siegfried EC, Simpson EL et al (2024) Dupilumab safety and efficacy up to 1 year in children aged 6 months to 5 years with atopic dermatitis: results from a phase 3 open-label extension study. Am J Clin dermatol 25(4):655\u2013668","DOI":"10.1007\/s40257-024-00859-y"},{"issue":"1","key":"5546_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-93750-3","volume":"11","author":"S Park","year":"2021","unstructured":"Park S, Lee JH, Park JH et al (2021) Ocular surface disorders associated with the use of dupilumab based on WHO VigiBase. Sci Rep 11(1):14293","journal-title":"Sci Rep"},{"issue":"12","key":"5546_CR27","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1038\/s41433-020-01379-9","volume":"35","author":"MZ Popiela","year":"2021","unstructured":"Popiela MZ, Barbara R, Turnbull AMJ et al (2021) Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae. Eye (London, England) 35(12):3277\u20133284","journal-title":"Eye (London, England)"},{"key":"5546_CR28","doi-asserted-by":"publisher","unstructured":"Saeki H, Usami M, Suzuki K et al (2025) Real-world safety and effectiveness of dupilumab for the treatment of atopic dermatitis: two-year post-marketing surveillance in Japan. J Cutaneous Immunol Allergy 8 - 2025.\u00a0https:\/\/doi.org\/10.3389\/jcia.2025.14794","DOI":"10.3389\/jcia.2025.14794"},{"issue":"3","key":"5546_CR29","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.det.2017.02.002","volume":"35","author":"JI Silverberg","year":"2017","unstructured":"Silverberg JI (2017) Public health burden and epidemiology of atopic dermatitis. Dermatol Clin 35(3):283\u2013289","journal-title":"Dermatol Clin"},{"key":"5546_CR30","doi-asserted-by":"crossref","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E et al (2016) Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. New Eng J Med 375(24):2335\u20132348","DOI":"10.1056\/NEJMoa1610020"},{"key":"5546_CR31","unstructured":"Study Details | NCT03050151 | Study of Dupilumab auto-injector device when used by patients with atopic dermatitis | ClinicalTrials.gov[EB\/OL].\u00a0https:\/\/clinicaltrials.gov\/study\/NCT03050151. Accessed 2025 11 09"},{"issue":"1","key":"5546_CR32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HGM et al (2002) A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 11(1):3\u201310","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5546_CR33","doi-asserted-by":"crossref","unstructured":"Zhou J, Xie Y, Du P et al (2025) Analysis of differences in dupilumab-associated adverse drug event signals between children and adults based on the FAERS database. Eur J Pharmacol 1005:178103","DOI":"10.1016\/j.ejphar.2025.178103"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05546-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05546-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05546-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:04:15Z","timestamp":1787670255000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05546-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["5546"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05546-9","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"8 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study utilized publicly accessible, fully de-identified data from the FAERS, with all personal identifiers removed prior to public release in accordance with FDA regulations. Thus, ethical approval was not required.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Human ethics and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}